Xponance’s Avidity Biosciences RNAM Stock Holding History

Xponance’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,143	Closed	-$659K	–	1719
2025 Q4	$659K	Buy	9,143 +1,156	+14%	+$74.7K	﹤0.01%	823
2025 Q3	$348K	Sell	7,987 -894	-10%	-$36.1K	﹤0.01%	1092
2025 Q2	$252K	Buy	8,881 +345	+4%	+$10.3K	﹤0.01%	1218
2025 Q1	$252K	Buy	8,536 +579	+7%	+$18K	﹤0.01%	1162
2024 Q4	$231K	Buy	7,957 +791	+11%	+$33.1K	﹤0.01%	1237
2024 Q3	$329K	Buy	7,166 +745	+12%	+$32.3K	﹤0.01%	1060
2024 Q2	$262K	Buy	+6,421	New	+$184K	﹤0.01%	1089

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Xponance's RNAM Position: Q1 2026 in Review

Xponance sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 9,143 shares — an estimated $659K sold.

Xponance first reported a position in RNAM in Q2 2024 and held it in 7 quarters. The position peaked at $659K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Xponance reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Xponance sold 9,143 Avidity Biosciences shares in Q1 2026, an estimated $659K.
Xponance first reported a position in Avidity Biosciences in Q2 2024 and held it in 7 quarters.
Xponance's Avidity Biosciences position peaked at $659K in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.